0001104659-24-084615.txt : 20240801 0001104659-24-084615.hdr.sgml : 20240801 20240801070047 ACCESSION NUMBER: 0001104659-24-084615 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240726 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240801 DATE AS OF CHANGE: 20240801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Passage BIO, Inc. CENTRAL INDEX KEY: 0001787297 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822729751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39231 FILM NUMBER: 241164156 BUSINESS ADDRESS: STREET 1: ONE COMMERCE SQUARE STREET 2: 2005 MARKET STREET, 39TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 2678660312 MAIL ADDRESS: STREET 1: ONE COMMERCE SQUARE STREET 2: 2005 MARKET STREET, 39TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 8-K 1 tm2420570d1_8k.htm FORM 8-K
false 0001787297 0001787297 2024-07-26 2024-07-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934 

 

Date of Report (Date of earliest event reported): July 26, 2024

 

 

 

PASSAGE BIO, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware 001-39231 82-2729751
(State or other jurisdiction
of incorporation)		 (Commission
File Number)		 (IRS Employer
Identification No.)

 

One Commerce Square
2005 Market Street, 39th Floor
Philadelphia, PA		 19103
(Address of principal executive offices) (Zip Code)

 

(267) 866-0311

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 Par Value Per Share PASG The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 1.01.Entry into Material Definitive Agreement.

 

On July 31, 2024, Passage Bio, Inc. (the “Company”) entered into a series of sublicense agreements (the “Gemma Sublicenses”) with Gemma Biotherapeutics, Inc. (“Gemma”), a newly formed genetic medicines company co-founded by Dr. James Wilson, who also serves as a consultant to the Company as Scientific Advisor, for the outlicense of PBGM01 for the treatment of GM1 gangliosidosis, PBKR03 for the treatment of Krabbe disease, and PBML04 for the treatment of metachromatic leukodystrophy (collectively, the “Outlicensed Programs”). Pursuant to the Gemma Sublicenses, the Company will receive (i) initial payments of $10 million for the purchase of clinical product supply; (ii) up to an additional $10 million contingent on the completion by Gemma of certain business milestones; (iii) up to an additional $114 million in development and commercial milestone payments; and (iv) single digit royalties as a percentage of annual worldwide net sales in exchange for sublicenses to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical trial materials and product supply related to the Outlicensed Programs. Pursuant to the Gemma Sublicenses, Gemma will also be responsible for all payments due to the Trustee of the University of Pennsylvania (“Penn”) under the Company’s research, collaboration and licensing agreement with Penn, as amended (the “Penn Agreement”), related to the Outlicensed Programs. The Company also entered into a transition services agreement with Gemma (the “Transition Services Agreement”), pursuant to which, the Company will provide transitional services at cost to Gemma for a period of up to six months from the effective date, and be entitled to reimbursement for transitional services performed retroactively from March 1, 2024, related to the transfer of the Outlicensed Programs.

 

The Company also entered into a research, collaboration and license agreement with Gemma (the “Gemma Collaboration Agreement”), pursuant to which (i) Gemma will conduct certain preclinical and IND-enabling work for the Company’s active research program in Huntington’s disease and a currently paused research program in Temporal Lobe Epilepsy, which were previously being conducted by Penn under the Penn Agreement, and (ii) Gemma will grant the Company options to conduct new research programs in four new central nervous system (“CNS”) indications.

 

As a result of these agreements, the Company and Penn also amended and restated the Penn Agreement, as of July 31, 2024 (as amended, the “Amended Penn Agreement”) to (i) terminate the Company’s funding of discovery research; (ii) terminate the research and exploratory research programs being conducted by Penn; (iii) terminate the remaining options the Company had to select new research programs in the CNS field; and (iv) terminate the transaction fee due to Penn as a result of certain corporate transactions.

 

The foregoing descriptions of the Gemma Sublicenses, Gemma Collaboration Agreement, Transition Services Agreement and the Amended Penn Agreement are qualified in their entirety by reference to each of the Gemma Sublicenses, the Gemma Collaboration Agreement, the Transition Services Agreement and the Amended Penn Agreement, copies of which the Company intends to file as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 1, 2024, the Company issued a press release announcing the information described in Item 1.01 above. In addition, the preliminary, unaudited amount of the Company’s cash, cash equivalents and marketable securities position as of June 30, 2024, is approximately $91.8 million, which the Company expects, together with the initial payments to be received from the Gemma Sublicenses, will enable it to fund its operating expenses and capital expenditure requirements to the end of the second quarter of 2026. This amount is preliminary, unaudited and may change, was prepared by management and is based on the most current information available to management, and is subject to completion by management of the financial statements as of and for the six months ended June 30, 2024, including completion of the review procedures, final adjustments and other developments that may arise between now and the time the financial results for this period are finalized, and completion of the audit of such financial statements.

 

The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

 

2

 

 

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On July 26, 2024, Mark Forman, M.D., Ph.D., notified the Company of his decision to resign from his position as the Company’s Chief Medical Officer, effective as of August 2, 2024. Dr. Forman’s decision was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. The Company has initiated a search for a new Chief Medical Officer.

 

Item 7.01. Regulation FD Disclosure.

 

On August 1, 2024, the Company announced the appointments of Susan Browne, Ph.D. as Chief Scientific Officer of the Company and Stuart Henderson as Chief Business Officer of the Company, each effective as of August 1, 2024. Dr. Browne has been with the Company since June 2021 and was formerly Senior Vice President, Research & Development. In her recent tenure, she has brought scientific leadership to the clinical and preclinical portfolio. Mr. Henderson has been with the Company since February of 2021 and was formerly our Senior Vice President, Investor Relations and Corporate Development. In this role, Mr. Henderson has forged the Company’s agreements with Gemma and has developed relationships for the company with the investment and financial community. With the contributions of Dr. Browne and Mr. Henderson, the Company has executed a pivot in strategy, focusing on exploring the benefits of elevated progranulin in multiple adult neurodegenerative disorders. 

 

The information in this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 7.01 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
   
99.1   Passage Bio, Inc. press release dated August 1, 2024

104

  

Cover Page Interactive Data File (formatted as Inline XBRL).

 

3

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PASSAGE BIO, INC.
     
Date: August 1, 2024 By: /s/ Kathleen Borthwick
    Kathleen Borthwick
    Chief Financial Officer

 

4

 

 EX-99.1 2 tm2420570d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

 

Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson

 

Entered new strategic research and collaboration agreement with GEMMA Biotherapeutics to advance genetic medicines for CNS indications, including Huntington’s disease

 

Transaction expected to extend operating cash runway to the end of Q2 2026

 

PHILADELPHIA – August 1, 2024 – Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that it has entered into a series of agreements to out-license its three clinical-stage pediatric lysosomal storage disease programs to GEMMA Biotherapeutics, Inc. (GEMMABio), a newly formed company co-founded by James M. Wilson, M.D., Ph.D. Through the transaction, the company granted GEMMABio exclusive, worldwide rights for the development and commercialization of PBGM01 for the treatment of GM1 gangliosidosis, PBKR03 for the treatment of Krabbe disease, and PBML04 for the treatment of metachromatic leukodystrophy.

 

Under the terms of the out-license agreements, the company will receive initial payments of $10 million for the purchase of clinical product supply and up to an additional $10 million contingent on completion of certain GEMMABio business milestones. The company is also eligible to receive up to an additional $114 million in development and commercial milestones as well as future royalties in exchange for sublicenses to relevant intellectual property and the transfer of clinical trial materials and product supply related to the licensed programs. GEMMABio will assume all remaining financial obligations owed to the University of Pennsylvania for the licensed programs. Passage Bio will also provide certain services in support of the transition of the programs to GEMMABio at cost pursuant to a transition services agreement.

 

"We are excited to have out-licensed our pediatric lysosomal storage disease programs to a company deeply committed to advancing these promising therapies for underserved patient communities,” said Will Chou, M.D., president and chief executive officer of Passage Bio. “This transaction is a key initiative in fulfilling our strategy to focus on advancing our lead asset, PBFT02, in multiple adult neurodegenerative diseases while continuing our preclinical research in high potential CNS indications. We have further extended our cash runway, providing us critical time and resources to continue to generate meaningful clinical data for PBFT02 and explore its potential in additional patient populations.”

 

Additionally, the company entered a new strategic research, collaboration, and license agreement with GEMMA Biotherapeutics. Under this agreement, GEMMABio will undertake specific preclinical and IND-enabling activities for the company’s research program including for Huntington’s disease, which was previously managed by the University of Pennsylvania’s Gene Therapy Program. Furthermore, GEMMABio will provide Passage Bio with options to initiate new research programs in four novel central nervous system (CNS) indications.

 

 

 

 

 

 

"By establishing GEMMA Biotherapeutics, we are able to further development of promising genetic medicines for rare patient populations, and we are thrilled to advance the three therapies from Passage Bio, each of which targets a devastating pediatric disease,” said James M. Wilson, M.D., Ph.D. “We also look forward to continuing our research and collaboration efforts with Passage Bio, which will leverage our combined expertise to explore new frontiers in CNS research. Together, we are poised to make a profound impact on the lives of patients around the world.”

 

In connection with the agreements with GEMMABio, Passage Bio amended its strategic collaboration with the University of Pennsylvania’s Gene Therapy Program to discontinue its preclinical research programs, terminate its remaining options to future CNS research programs, and terminate its funding of the discovery research program, effective July 31, 2024.

 

Overall, the net impact of the transaction is expected to extend the company’s operating cash runway to the end of Q2 2026.

 

About Passage Bio

 

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.

 

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com.

 

About GEMMA Biotherapeutics

 

GEMMA Biotherapeutics (“GEMMABio”), a new therapeutics company, will serve as a research and innovation company to speed the research of and global access to life-changing advanced therapies for those living with rare diseases.

 

 

 

 

 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones, including the receipt of future payments under the GEMMABio agreements; our expectations about GEMMABio’s ability to execute key initiatives; our expectations about cash runway; and the ability of our product candidates to treat their respective target CNS disorders. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop and obtain regulatory approval for our product candidates; the timing and results of preclinical studies and clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; failure to protect and enforce our intellectual property, and other proprietary rights; our dependence on collaborators and other third parties for the development and manufacture of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions; and the other risks and uncertainties that are described in the Risk Factors section in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

  

For further information, please contact:

 

Passage Investors:

Stuart Henderson 

Passage Bio 

267.866.0114

shenderson@passagebio.com

 

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com

 

GEMMA Biotherapeutics: 

Kristen Love

klove@briancom.com

 

 

 

 

 EX-101.SCH 3 pasg-20240726.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 pasg-20240726_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 pasg-20240726_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2420570d1_ex99-1img01.jpg GRAPHIC begin 644 tm2420570d1_ex99-1img01.jpg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htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover
Jul. 26, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 26, 2024
Entity File Number 001-39231
Entity Registrant Name PASSAGE BIO, INC.
Entity Central Index Key 0001787297
Entity Tax Identification Number 82-2729751
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One One Commerce Square
Entity Address, Address Line Two 2005 Market Street, 39th Floor
Entity Address, City or Town Philadelphia
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19103
City Area Code 267
Local Phone Number 866-0311
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 Par Value Per Share
Trading Symbol PASG
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !8X 5D'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " 6. %92CTRE^X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2@,Q$(9?17+?G61;1,(VEXHG!<&"XBTDTS:XV0W)R&[?WFQLMX@^@,?,_/GF M&YC6!&F&B,]Q"!C)8;J9?-NPI@:@%,#5/ M#*>I:^$*F&&$T:?O MJ%6*I_8DL'V#DY);>DQG&LQU7)Y1T$O#T]OI1U*] &W:9_+K:WN\>F&IXLZ[X7<7%3@C)N5PW[[/K#[^KL!^LV[M_ M;'P15"W\N@OU!5!+ P04 " 6. %9F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M !8X 5D/F16SHP0 .D1 8 >&PO=V]R:W-H965T&UL MC9AO;Z-&$,;?WZ=8T:IJ)2? .OYWM2TYCI.Z=TUH\-U)K?IB#6NS"K#"\B $SCW_,#L\,C'=2/>41YYJ\)'&:3ZQ(Z^RC;>=!Q!.67\J, MI_#-1JJ$:=A56SO/%&=A&93$-G6$W[ M)J \XZO@N_QHFYA+64OY9':6X<1R#!&/>:"-!(./9S[G<6R4@./[0=2J?M,$ M'F^_J=^6%P\7LV8YG\OXFPAU-+&&%@GYAA6Q?I2[W_CA@GI&+Y!Q7OXGN_VY M/<_U!)><,TFXZ5W!%ES@8U MLU%>:AD-<"(UJ^)K!=\*B-/3N7SF:FQKD#('[. 0=KT/HR?"?B_B2T+['4(= M>O7?'#BT\(Q%4%<86JS( @+"EN M8[9MHL#C-RS..<+1JSAZYR7#XTK(D"S2D$#Q->8%5ZK*J*V.^A5:'Q5)8V)PG6\F>_/ M[A8?KID%QQ2&]H :NAZVHZ]2.Z9P#N$P#J3*I2K8. M\37< 40J,I<%)!3R*L/&A6Y1OUE@D$>V[IX#.0M#,,.\\[9!/L-YY"%M)L,E M(>H#@;^Y3!*N D[\[P53F*&XM?V[J'OCN*N=;,3%)6$NZ9$_F'J"T0:.0X/L MD.Y(1V">4BJ,NFX*+F[K[ZGG9@]*8"5W:2,Q+N=%(F8AC[-(,(RO[AXB+ M-X!R&6+N[ZGV4 .?$BF6+=K$5DV.]?.%T7];ZZ9;BX MTW]30FN>EAY0I =CSANI<*&V6<2MVX6+N[LO8Q$(+=(MW.T:)A(6-_+@*FT\ MM&X/%#=P3_&+P%@DW%_[D1&F-AAN'S:;YO5KT6LEJWL"Q0W\?V3+/"^ K!40 MEVT%/'H(P"U[)33,;7)#7/KS^A?B\Z" >FL<2%J43'W*M&Q7OI;!4X?\Z%R: M,85X3)&O+"ZXF5Z)'^$=C-:]@.+FO5(L-#7HOR9KV5B!+0(PXMUA)+7K4]RA MW])&%B]!Q-(M/SESM@C=S_R;V9\84VWW]"R[7\#@L#59N@,%:,6P3!E+FQ<8 M%]2J0->M-GO:\L1@W@_PD-Q+N%,E^9)SHB,.N=/FK@@)K&N:BW+^W#_N-,+B MOW'R#K&/'MS-2Q 85R ].8GY!H2W?*^QWM,S*9_FUU%HFY6;$8690 MY@3X?B.E?MLQKP>JMSO3?P%02P,$% @ %C@!69^@&_"Q @ X@P T M !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV M!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-S MS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L. MIM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ# M%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6 M#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#H MG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK M'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.? MK7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'- MM[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?] MK-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7 MCX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L M"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ %C@!69>* MNQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %( MMB6/:(7->=I3W;+T]! M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B M':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQF MN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1 MP74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\ M]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48Y0]02P,$% @ %C@!620> MFZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W M;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9 MHIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJ MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( !8X M 5EED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"% MKQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/ M$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4 MZ]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N M6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC M JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@A MLO7L^T%.6X.^D&PO=&AE M;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( !8X 5D/F16SHP0 .D1 8 M " @0T( !X;"]W;W)K&PO&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " 6. %999!YDAD! #/ P M$P @ 'P$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 .."0 ) #X" Z% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://passagebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports pasg-20240726.xsd pasg-20240726_lab.xml pasg-20240726_pre.xml tm2420570d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2420570d1_8k.htm": { "nsprefix": "PASG", "nsuri": "http://passagebio.com/20240726", "dts": { "schema": { "local": [ "pasg-20240726.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "pasg-20240726_lab.xml" ] }, "presentationLink": { "local": [ "pasg-20240726_pre.xml" ] }, "inline": { "local": [ "tm2420570d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://passagebio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-07-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420570d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-07-26", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2420570d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://passagebio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-084615-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-084615-xbrl.zip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

[ I(O%IY@A;SN//.&)SKQSB!_!O^ MWO6U25O[-'[\=N_.I6\&!4RK5QA[YMJ>G3Q6G#L02EM?37=^W+\]":CQI5[G MQ[>_W/CLS65HBI!"3=U3*]7?.EP*Z<*ZANN!C)@NM006;,STP#='6/( M\[X M"P@]@.\$&?\R0XNGJS_-R^_0?-4]1N=KU>[7XRO;/KOXRNBC[8N6JGPGUP0/ MLIWIO4L:E&YM/5/?WPV1_^" IP/''MA )2]<;9=2'S MV=XN5:IJ3M[S/"2$!8\/5$60A^I=)4PC;TB#SW,Q2.;I58E$=' M6B]Q/_X'ZKYAGUE.#Y[X;#7G,BO?4HOU8*W&@ $3\6B9NJ[G@!O&"D;7&9,N MLYP[%#=\B$))=DO'2L^TP 00DX,]\)EM, -/SKDY#"R?VLP)N#4A'/)PWIN( MF>$$IPNKRO0\/,I.G&0$ =$W)Y$SWJ0LSIW. \+H"96)/C^B@3[I_+V9)X^ MF\?_7-Y^#U$"S.='<3 1&^^G$5$(O5+6MDP[&RI'M?)KS_1A(S&%#>RP@L+S MW>'=]?GHRY?*^61W3G'Q&EB![.$KJX3O=QW'8M06'?XSCC55 L\E0^[F[L%< MWXK1&_P?3DYT%2__HZ=6(FZBCP0-"]G4MD*Y3O=MB':--76'-(XNB%:ME&'@ M^C2.C(/(I[)'?\0_E2EVP'7HL#%V_P0,'U@_*U_V+>O8^-KTOQSY>R]!]E-' M%5D:[BOXTYD/DOUAN$Q6ZM5-6E*UA."GNI1BL=^LE.7(/Y+_RPS_N<=$W1)B M2-$[BL[<.^OUYB5#5\/QWL?J!^Y\T5^"!J1.E^;3AE: M4F6ES37]?EH2CLW5DJ2>W.=5IM^C0O=KENS6$J&K3-F8!TF?F^V;)JJP<6$* M!SNVO\)RQ#_MM%7:)E2+A'V2T'*D-$18FD(-36'T22386GZE(49W8R H$!W6^H#H%N5\6:%^804G?.B9_8$___%<9?YY-FFK9Y-'C2B^YI-A MU['6EI]FO&PFK5Z6L.TV)4HL,OQ@5NX&)GPRM3V/..):H&V/YF/X',MHJ^1R M-BR)CJ]#0SQ1M:[0O?PP1/UV:NV<7^M; 7OV%L94 )+J YC%O5##>,21)9>. M[^BW1?+O2AG//\DY]<@G:@6,G$,8(-Y,7Q27K'A;5[AQK7#C0A/0$=H_)[EZ MUS2L?OO;U_/-7[MKJ7:%%.*B+?[M[[D31S,J%,65\]\V\%3[O7V^]I:5'3S8<^ M%JR2-:1\YT 4H:/!L S(CXOOD.#I(T)2P&B7M!Q8>6\@QD Q29O.2X MKXS% MLPS]Q;LL[-SB5SFS.+?"#55F-C2EB=FWS&5?4#3YK9C;D%/S[1EWMD;M3WO? M-'MG277B9XL1OA?,UB)R6IIR42_4QG/]R_-OV#,:AX=*3;NGS#<&V*J1:UG, MS,'K .R&,,1@-VQ')/,!9V(48!@>[^(U"*9(\.7%2+CI8BUK@H)[9\+2*+(V M$ ]//#8R.[QKQ*0G6-QI6$I)DISU., MH[1BC"]CK.5;LOE:T:B/_,F[=^U.[XF5(J="5ZWD:$4&[Z65N5_W5MFON*1H M6?B8N,3H%[\%N+(7>U9M M$0MF+[Q*[HL;[DIV=8_1VU*7@5H!AJ[ .+GB=LZ"B,4#5TP*PTKE('7WP>]\ M;K*Y%Y9KVCX;2JK4$0 CUOXTB'V!SDD.I F38Q.3='26^][3)P> M)":NZI@KG^DKV$8I]/1W Q.O=#BS%7&K M0U65MSH406'%=:SDT'2*I&WK9;*&/A+[-C6@%]O.:V$T!2Y#M(^*9^K!>N0Z M18XL$@78($HX(,5$#S8/NI8)*31$ #3:(R[@*RGX;]EP2$DG'LTS*XF80 X# M1#&=H2X+0,AXA'06X"R0(N &(050+UH@#=)G-@,0"OQL@J8 SE&PK#NE'G(/ M!D'$T_3*Y#W%';@V+8[7B]T-@%#X$6D=P><0]6 #J\U%TYJ(/)")C6DRU='- M\)4R4C<@GG&\H@A[<)@3^"'A"C#M_/#M246-'_I@K'QD'#+T[8E*^A"Z6*;# M30/^!_+/#X\O*M7\\<<>[789,2!^HIP! VP#QI]\J&SFC\#6,280VCGN8$+6\"@"XZD1LR FS$C)64P&+.(Y?8\.,QM9)LG[<1!$9N^+ M*=;=F98%6:O.4-'7S'4BE!X[1>A$BA.@_6^U0D!1+(ST(KH@"H0HCXL[#G3+ MQ&-""V-$(X#B\D(9 LA46\%$HQ!5GS MO ME@@LO 9S0D!4NN-U+O,1' M"@J6U.$N9C#TUT94BU=1*")@1L C:I1=PG[$HD;BR37$AOB_Z3,^9;?.) M!>PQZ8P]PD<9FR9.I96$L,>]\H .HR"^17GZUPW?Y!5,D71@ZA.;5&D=<8VB ML$1#F6=E[3@.F7K+C'U4[L7ARZ1A0_[-F/]$>H?6$5^VF455;DK*W82%;JH8BHK% = 63L3I9 )$D FIT3XBNYP 4 2("0ERF%! *1R M3AI/@Q4S2#H/8B:N*+6L]9$B%9.,6H&B :Q0WLFJ"WB@>'086X@U( 8*/ _P!WET:8!RE0.%7+(A M7DY@D0\.*$'+!:?F\DDQI.L.^([8CTS9^]]EB'%(G@C(%&''IDT]:;-6##UB MFCU]49Y*:KSCRK8A8&C$.RPXS2(L7"($@YYXJLM;V^%G;P3H*1RB(S:)";I8K[CT0)/%"20]E67? HT]B*0A# MQ#2$6$20,C9V+<>384Y6=H3P*DGA%3A'X> LW"%HKL EDLT$"DE=@54UD9[$-"$,8[Z MA)WMX=4O5)X[C@=FUYS-E&.E_!B(:^? (H17;P)>XI4QM5+Z&'NN[W(4D4AU MF NVN LQ=;4BK6'[*QK?H_B( MI $F1VQG>84]D\N1C'BRZK=&GRSP.[.5>M"'K&X:-:>$%QN;,;!QQ;T"F/[* M8,>&5 6KJV*T:<=?AQ5:D*Y47;%G6-(DH'@C5B;M:>8O%E( KF6B8?8@ IL M&L!#7'"(!UR16L]JATXY1J+P-Q%?]029.R:JJ*5#T?\@:L)\>K#N.J%N1Z[6 M9B12DJ*"G0#XKN;8Q/P;=.[?>VIY-RI)%'-T&IP>."&T+DY?-A>(6%?R8J8^ MXX<9MBCA&-.<2*;A25LEA4>$:R)2!6#"0*"'QLLHB2.E';B."(B:A"B04-?T M84GQ(? O\' ]8(S'8A1$%F8;$4>!-Z @2F1 X%-@Q788N&..BSR1>V#BT6+^ M)@E^3\+7IX%/5 QUJ2<]/<@?[4\-* #"KSTSHBK2$))))0R84R)$1]2T!/V M^!1(,8+"@^XWC %$Y)JL1"46C-Y[C0V"B+\D.Z00(#!84X0#B9Q5VM*TA$Q? MU4\N&+]V.S)!W4!^=&8 ZT$J<%7(.@Q\R7L8BZ:\PBQ1W<+XAOK(0H5ZD$: MG/AWC-G$=NYBE^.#_LZ0XH7V3[H!DTQNKH[HTP&!>;!4DL6"(9*,0G\[L+&H&41"/0DMI6 M\E _6_F/;M"[0S%+Z ^"L4S:-2VYL$ %9)*'V,&\$%&NJ*H0*55;H^MKVGH. MVHE>J"78IB=EJ^2S.XW!>2BUA%9JZ\4U@LC>6NL?"B^#X_$R4NGCGL)Y"(U)/7']U"?-31"CR;J8IO 6'X=H!!&Q"F/81>"A9![(Y&1X_RUEY M7A]^Y@#Q?B>^J2\1E$0>$/S.D'U2]T"I].A[!9$1IPZ2IZ6.Q:-9HLOCGWM@ MGR=V_[!S^RVP1)ES^R;&0B(< ZO8A'!,]QV/H]UHA$6%,W$;E\AJ00"LH"3-WST#I%!X/*[/"G:Q#(<\ +SN&?W/DO6/L9 MVPRB+X\HBKYL$3L@V)-RLUPDYP/Q#_@D6>I()AAY?>-S5P.Y0(]H@!O!BUWD M:0H'"1;)AB(BQ$0"E)=1-08FZY$3; 2 #,4EV+BW$;&S&&JJ(7E!=$9((F: MUL,C+# ;$"V0LF(($:LBHNX)EAEG#L12=6E;# +'CYF).,(1>::33(' A12! M*+QL@0F%PX8E,+ZQ<#$E,OI 'ZRAD1TTPEERW'/P^RG("RN_8 M_W1FDT6UF+#H$EH*.G4,'!6K$W P%8>>ST+:@TDKY3G3?A"(^4UH1073' MQW( >2=>8^?26,CYAU%'1_[LHBC"*G.LA9JT%A)!H9==3'4SZB_O8!/Y-\R2 M*0>:$GEM&]C4#K--4-]/@ F15!8(3JHR&."(K(G_%[W M8AI7P098MI]V1=-CT6D'6^)@%Q<TV:Z6-/D93,BO+JJ@-4_EVLK3%$;(PPLCRE,51LC# M"B/*TQ1&ENS#;,U#>7C-@SQ!S4/)UCSHLU0]?I-X:U'ZNG:4IYT5>FS+NG?%G%3:2= M)20(%K.=.X^Z,4I[J[[)(MP?R=53I[SLIH^(-7]-=V+^F_1+7Y6/JVE+;O#8 M6_D-'LUI)\:"^SEBPG*)!4' 66\*6HH9>?-C]N7M;:YA>DW)P,.W]?RAMJE5 MMG8JAGK#QGM[);4\\(>Q5.,K]R7@'";H^U'?PRJ9A?7]F#TT7RKFB?X"$7G9 M1"=?6XE">[T\?3L-F.;4:89 S?]YXJI5-695^PCU<%:X-;)43I7W( MQ, 8A'VC3>I3^25/:S),$XD'Q&4V1#6,?#Z\^"!?V7^RRQE6["J7G^M4_Z>. M<*I_CG">^,K^3OOM:?WRZJ+U>WV-=J$V^_9-J@OGGMFLDG.E@(&'";KL*)?U M&]F/(+-J+/7+MAJL5709Y%X]3+(0D$C6P@&0W;$ DST!C@;^P/&P5>2)&K)? M1.Q[/Y>P)'A:'!*L,NH+ORB9)+XH>7GLM[!>G_QVIX=YRNEW:CY^ZN;.7_<. M/9^8N_B=[OOS@J%[QW\K0^=PLG^/J[[FNLPGQFZ#;Y!CZ@\LK%T?8M7FSM1O M?T(0'QZF/3@T7QGQ_[.$R\.>:9DG/.UYZLO$GCU>W4ST(7W ;_OYYP>MF_<. M6I_GVHX4"7Z$[]@8'Y!V4_QP4]D]O!&7)HEOJQ%HB&GL_?CHFU$Y[M_6/PZ^ M;M2-\3?M[';R>71B[MRZ']IMLV-JD^J[Z].V,32JK]Y]'U:[1V?FE^OZEQ\C M^ZQUW;[5+>_[X6!XMKMS7#_O?C6<\;AA7EY-AM].MR]VOE+WU>'(O##\=YW1 MMUH5/_YFG'VO7U]]UYI'JG?:3^<_G6E,AQ'H]O3 M$\>QNF?#X!V_^-RH7%^8U\VKR\GAQ+5&]NJK M>KWN5[XW)$#DY+3$N:'1M[5QK1F^JD#[H(DJMW%&L!29G]]S[W /OB0[;1)E%K)3(;2 M$@MY#^O@]>79Z6&_=_#ZQ=%S? KZ[^#RY/+TQ>'!H_");Q_%KP^.WS[_ MA[BX_,?IB^_N34WA]\1XI_3B4N?*B3?J6KPSN2P&X<% 7"BKI_?P(EX][[XW M=/K?*KR\+W)I9[K8$SOW#@]>OGUS>X?WBXDK]P\>T2*0=[YEXR\AJ',B MEN[L"Z\^^J',] R/K)[-_><(.3@^?/%QKB?:BZ=/1^.#1\>'OS15]W[1K6Z! MK9_EX5W M]VZ+QEOBS*^JX(DJO+)?H.'GTCDY4^)8&_&V\L-,XU6G7+]W.;=*B7.5:NFM M3L0K52AQ.5=6EDMQ;LW,RMP);\2K%V=G1[2!YR]5Y77BA"Q2\8*(B!=03DF; MS,4SDV5R8JSTVA2_DDW=NG_Y0O:?'+ZR$BM3H3XF6>7T0@WZO6MCL_1:IRJX M*2>FQ@KP5J1JH3)3YMBF*E+<<;(4S^THL/\'2:P]&XF? M=.9(#T[NMAZPI8!'Q#JP6'HUTTF_9VNK">+N6(Z0,Y@GJ\*U]O,;C!!2DNE" M%HD2,Y@OR3&'02>Z4$&MGKVY$+K $]X4=](%%#'5Q4R\K@J/3V^*^]9]J,P^ M?$+4E3LOKDN8K9,)"T)]+%4"&^[WP&ULIB J4RH2$[B82#<7MBJN)=L,F3$O MF(J_[8K=G=TG7P\OOR3:O#XY/7K^XA2?1^)^D8(Y^^*HFE7.!YK&\'_@RF,* M#,V"3HP:A&4G13(2#]X<73P_^MN>.#^Z>/60'$^2Z0*JG V=I_6;*E][I:E) M*@=S@_AT7EJS(%&1;#*X8 ?I]'LEY =U<,&\"E59DRK:D02[:-PF>.%-"N'* MHH"?2["IGTLO !KGT@D5[5H79(K"@6V\?VN^;*2FC;QX$X\X]JY>!R0UL3A; M.N,@D S. @YAUI CRL\%YA4.\@HL>!C==D:LL>#7#?Z;W7:_U_CM 5SX\Q&B MRAP? ?65+,Y,]*W%C+@!_6&LQCQZJ,[H4_\]Y&OWUL-?8$$)3V_@N\^$PLW MUG\Z.&ZN7PF6_=YJM!S=#0-_#S6)K%$V9S6G7[K*W:H]#+VK%M;PCXGA6,>R+)BF3-6 *E'62UVT"CN!ML*9.'I=P?[P,^E^ M>Q<-] OK$ I114\R18?75]M.ROAQ2PN.NEG=.V<*N)=K!:[A0JA=!L,# M$2' */1#0/IK3,?^DHP\1KQX=-IXIU'+318\''R50SM8!W)PF_SQ5!= +C@" MQ@WJ9P&B"'/=;OR^ $^MTZ"9[%\5A5MFN)B6C8YL.;N;\X3C25H'- M7+OX.P*ECN"8PIXE$1$9$0_P3A7Y)US]ODT)& LG=4H1,1//YJ:J@V()] Z% MJFUXKM445U5)Q?C!3*>X(EM61Q]'XG[&>U[.X44Z092=2K]WI9;1._K@*&'Z MV917.[L$^T5>P77 [V$U?OH$ MXD&&.H<7$L%I5O6VN&[C(IJ\!?O.$O91Q $BI(?5I98G^$T 3. ML&D'/@^BA=)YN%9BP86$G(/7Y#K 8IR*=Y+@XB)U['SC)12BM"37 IZU[BR5 M/GB+P O>"9@^,S9@L99TO>*U:X4H35EE\3)1(>Z\UO,B6JQBO1KU0V)6$ MMM&+P6HR&^#5!D;X1&8[$C78T!WG.5@+*VS 7EX!.SLD:1H6MZ*F=.K)F^=# M5<@)6Q#9VH)MNXD?\4YU#MRJ=O0WG8R97MG,FEL,";-)YK >!&Q0L="FQ_D.ED/AA6S$@9;@+(V MSXXSF5R),0YW)M,I"#A?W8\I:^][#@IQYI;C)TA3KH83!>T$C273W"7IR1:* MB,R?>V2',8^(,X$9_\\B_Z.S\3]@NV.$ >?)K[HY.,,N!E0!S5.UA1.>&OSAM)6JDU!([HD. M=N'"@QT*T$ 2F1*WY%)?"U)KC[^"#]=*WJNEDXCZ?@(9G(QDQES1Q:ZE33MH MIL9:GZ@+JRE>J\M6*W<(M'- 0/:G&#PSQC+Y!(QDU(-P"=IQ8K]78R *!V ( MSJ=>#L( (;B: "2^!JP YP8UETNC7>!QCL@+'D%V7$*B4AL"+ '2;JE--)4V M:7D9?PR/M\'^&C4,N!*$/-X'+-TF]QW@$8L77;7J;$ :OKK) M%$K"6W#FS4V)!*#$+C=>'Y U$$.17OQ091B7VF-T/U"H%@[\AE45["#1IU0\SX3'=F)-YR:4+C M,K'M0_0$O[%698V0H(8<2>5)OXG?$\"\-"'U]?6H M# 1-M!GA\(-'[P_OB'0:M[PU ;D[#GK[@,B#F'C4H#(B[H=(S,(L4^*?CE=J\[#M3J."&0W' 8X"6P\_U.'V^#56177;LBSZI#Q29VS^"W0UJ>RU2M]+9ID9-3:NA9>)70=W"A:S\-">BY MU0M*Y"]44MG0:3G%1VCNBW?D*_)^[RCDI^.G3[_M@%B 5<3QP@ (Z3QVC/>X MA!62UC@@$! 8P#IW=+B;QTW7T*P'J4@X2AY/:(C+"<"=7X8\FPA48K6[NV4O!$/>K)-S[X<*"56* MXH8@.?1CUW*(3M: Y9JKB&6LCL3\A6HP"* <$,)0BU-B34E$JR/]7HZD?Z(H M=G.DUZ&/Y2HJ-&(7'E*)NB9UWA1$ZT>-+-:_F2@ W\7&X\146;K^$"+4>6>/ M?J_^@CFWOIRB$?BW\7QF9+;^C,9CBHT#<>F-1S2OMOZPS&#!ZT0U[>2-U0#W M-"VT_IRPUL:S%3Z0 C"LJWD>2V:<*3O8029M;;PC&NPGJ;92A,HM3+:@H3MW M%=ZF04:>@F$#Y8%&9CV4J:(.;9@7@OY461A@3/64QH3JH2":(Z0:>L!H5DVS M4%/B41KH1GOX@ :>HN4%6^[81S7>/W M0XFK=04UR=Q2: N7SH, FFS@>OK*H!/VB'QQSB2:_0:CS;5E70^R=@VXR0\5 M7FR:O>V[;<-Y *:WH\1PU)! $7E/5B8M%>:9JYTA!!Y>P/6Q+9)S^/O )M"8 MPKU2=6Z=RBX#*\@G.F$ZPH),32ELLS\)ASQR_-<%MFG/1(8-Z!F].I4ZXZN6 MH5@3'Z4A?( M,12QUIC;W15$I#J)DSY=^F@PSFY_?Y_92+&F+0J$ $9"2$*WICNQQ_4:'MD; M=)P /;-:>:IXA3G:$$A255*/@#E<=%H#QKK.VXCV-D6PLRM3$.NU,NAQ-24W M8%68EMX,-NV6DL.,J\5?ST_6'2G*VA#4:%:J7C*MD%\26+$FN]'^6%T".8U3 MI:H>5,[Q+/$5S8B5E'<$18W#B<@L:<92.UN%)D0;0@.]G_2#G&,JEU@]"1I# M[[TCE7P)?A OG:JKZ3C%)%6<\N[,QTP)=T0/R35%$SZ;!DT''?&_HZI'.9]1 MW2A41A]J M)$&*,"]_ P0@&:H0>BS-U[&3H KCH/5QH7;M^LJ DV>00>H\M#Q M/(,:@W74D V3;WX-QWA+V?YMICF-+UYA5-D!^HG?NSOUK5J]3XH%5ZO=WF]- MP05*Q45/<>B/F=@C8??*7T5^?/!GMC,>/?W/+>'_HYC7_O]^L>=\M M4R!/?T9#*7L'Q^]P])F^PD.U5#;\?B%S<6S-=2'X7P.]5C+S\X0"W+,PY!R' M^,+J;\:[HZ=/QJ/=;W=VPQ-P.\>6$]KQ>R?S">UUMUB]M:J^=SNT_ C<0A'X M% #\%@SO*L.YWT^ 9 NHP%>G!E]0A?]F7[P-B')/G%*;[W=3E/\]5\A_R;\2 M\HC^=$GX6R;T)T_^ U!+ 0(4 Q0 ( !8X 5F)D,V>+0, .D+ 1 M " 0 !P87-G+3(P,C0P-S(V+GAS9%!+ 0(4 Q0 ( !8X M 5F5C.U#_0H ("& 5 " 5P# !P87-G+3(P,C0P-S(V M7VQA8BYX;6Q02P$"% ,4 " 6. %9C+]8O5D' #95P %0 M @ &,#@ <&%S9RTR,#(T,#&UL4$L! A0#% @ %C@! M6=%WPC.G'0 IIP !( ( !&!8 '1M,C0R,#4W,&0Q7SAK M+FAT;5!+ 0(4 Q0 ( !8X 5G\S !T;3(T,C U-S!D,5]E>#DY+3$N:'1M4$L%!@ % 4 20$ +I# $ $! end XML 17 tm2420570d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001787297 2024-07-26 2024-07-26 iso4217:USD shares iso4217:USD shares false 0001787297 8-K 2024-07-26 PASSAGE BIO, INC. DE 001-39231 82-2729751 One Commerce Square 2005 Market Street, 39th Floor Philadelphia PA 19103 267 866-0311 false false false false Common Stock, $0.0001 Par Value Per Share PASG NASDAQ true false